ImmuneCyte (Worldride IP) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
ImmuneCyte (Worldride IP) General Information
Description
Pharmaceutical assets intended to develop fully human polyclonal and monoclonal antibody therapeutics for coronavirus.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
- 185 Technology Drive
- Suite 150
- Irvine, CA 92618
- United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Corporate Office
- 185 Technology Drive
- Suite 150
- Irvine, CA 92618
- United States
ImmuneCyte (Worldride IP) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ImmuneCyte (Worldride IP) FAQs
-
Where is ImmuneCyte (Worldride IP) headquartered?
ImmuneCyte (Worldride IP) is headquartered in Irvine, CA.
-
What industry is ImmuneCyte (Worldride IP) in?
ImmuneCyte (Worldride IP)’s primary industry is Buildings and Property.
-
Is ImmuneCyte (Worldride IP) a private or public company?
ImmuneCyte (Worldride IP) is a Private company.
-
What is ImmuneCyte (Worldride IP)’s current revenue?
The current revenue for ImmuneCyte (Worldride IP) is .
-
When was ImmuneCyte (Worldride IP) acquired?
ImmuneCyte (Worldride IP) was acquired on 13-Apr-2020.
-
Who acquired ImmuneCyte (Worldride IP)?
ImmuneCyte (Worldride IP) was acquired by ImmuneCyte Life Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process